Beta Bionics CFO files Form 4 showing 100-share exercise and sale

Rhea-AI Filing Summary

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions dated 09/05/2025. He exercised an employee stock option to acquire 100 shares at an exercise price of $5.10 and simultaneously sold 100 shares at $21.00 pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025. After these transactions he beneficially owned 44,041 shares of common stock directly.

The option exercised was part of an employee stock option award exercisable beginning in September 2023 and expiring 09/13/2033; the filing shows 99,595 derivative securities (options) beneficially owned following the reported transactions. The form is signed and dated 09/08/2025.

Positive

• The sale was executed pursuant to a documented Rule 10b5-1 plan adopted on May 15, 2025
• Form 4 includes option vesting schedule and expiration date, providing clear disclosure

Negative

• Reported sale reduced direct beneficial ownership from 44,141 to 44,041 shares
• Exercise-and-sale occurred on the same date, leaving no net increase in long-term direct holdings from this transaction

Insights

Securities Analyst

TL;DR: Insider exercised options and sold an equal number of shares under a pre-established 10b5-1 plan.

The filing documents a routine insider exercise-and-sell on the same date: a 100-share option exercise at $5.10 followed by a 100-share sale at $21.00 under a Rule 10b5-1 plan adopted May 15, 2025. The transactions net no change in daily outstanding shares from this insider and reflect execution under a documented trading plan. Reported post-transaction holdings are 44,041 shares and 99,595 underlying option rights.

Corporate Governance Expert

TL;DR: Disclosure aligns with Section 16 reporting and documents a 10b5-1 plan sale and option exercise.

The Form 4 discloses the adoption and use of a Rule 10b5-1 plan and provides vesting and expiration details for the option (vesting in 48 monthly installments from 09/14/2023; expiration 09/13/2033). Signatures and dates are present, meeting standard filing requirements. No amendments or inconsistencies are evident in the provided text.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feider Stephen

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		M		100	A	$5.1	44,141	D
Common Stock	09/05/2025		S(1)		100	D	$21	44,041	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.1	09/05/2025		M			100	(2)	09/13/2033	Common Stock	100	$0	99,595	D

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.

2. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

	/s/ Stephen Feider	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Beta Bionics (BBNX) CFO Stephen Feider report on the Form 4?

He reported an exercise of 100 option shares at $5.10 and a sale of 100 common shares at $21.00 on 09/05/2025.

Were the sales by the insider part of a trading plan?

Yes. The shares sold were executed pursuant to a Rule 10b5-1 plan adopted on May 15, 2025.

How many shares did Stephen Feider beneficially own after the transactions?

The Form 4 reports 44,041 shares of common stock beneficially owned directly following the reported transactions.

What are the key terms of the option exercised?

The option had an exercise price of $5.10, vests in 48 equal monthly installments from 09/14/2023, and expires on 09/13/2033.

When was the Form 4 signed?

The form is signed by Stephen Feider and dated 09/08/2025.